Prof John Petrie (University of Glasgow, Glasgow, UK) discuss Metformin safety and efficacy in ASCVD.
1. Can you give us a brief introduction to the role of metformin in ASCVD reduction?
2. What is the REMOVAL study and what did it measure?
3. Can you tell us the latest data from the REMOVAL subgroup studies?
4. Can you tell us the rationale behind the VA-IMPACT trial?
5. In the light of the HOME trial could you comment on the latest ESC/EASD guidelines?
Filmed on site at EASD 2019 by Radcliffe Cardiology